Teva Pharmaceutical Industries said it expects to more than double its revenue to $31 billion in 2015, when the global market for generic treatments is expected to be worth as much as $150 billion. The drugmaker projected that one-third of its sales increase will come from acquisitions, a strategy that catapulted Teva to the forefront of the generics industry.

Full Story:

Related Summaries